natgillin/translations-raw huggingface dataset:
The active substance in Kiacta, eprodisate disodium, is expected to work by interfering with the formation of fibrils of AA, preventing the deposits from building up in the organs. 
Zdravilna učinkovina v zdravilu Kiacta, dinatrijev eprodizat, naj bi delovala tako, da bi vplivala na tvorjenje fibrilov AA in tako preprečevala, da se odlagi kopičijo v organih.
What was Kiacta expected to be used for? 
Za kaj naj bi se zdravilo Kiacta uporabljalo?
How is Kiacta expected to work? 
Kako naj bi zdravilo Kiacta delovalo?
This is a rare, life-threatening disease that occurs in patients with long-lasting inflammation, most commonly due to rheumatoid arthritis. 
Zdravilo Kiacta naj bi se uporabljalo za zdravljenje amiloidoze amiloida A. To je redka, življenjsko nevarna bolezen, ki se pojavi pri bolnikih z dolgotrajnimi vnetji, največkrat kot posledica revmatoidnega artritisa.
Pilisborosjenő 2097 Hungary 
Pilisborosjenő 2097 Madžarska
(Invented) Name 
(Izmišljeno ime) Ime
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANTS / MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, PREDLAGATELJEV/IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
They may also have episodes of depression. 
Ima pa lahko tudi epizode depresije.
The full EPAR and risk management plan summary for Aripiprazole Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Aripiprazol Accord sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
• schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs). 
• shizofrenijo, tj. duševno boleznijo s številnimi simptomi, ki vključujejo neorganizirano mišljenje in govor, halucinacije (bolnik vidi ali sliši stvari, ki jih ni), sumničavost ter blodnje (zmotna prepričanja).
To prevent manic episodes in adults, the same dose should be continued. 
Za preprečevanje maničnih epizod pri odraslih je treba nadaljevati jemanje enakega odmerka.
Since dopamine and 5-hydroxytryptamine are involved in schizophrenia and bipolar disorder, aripiprazole helps to normalise the activity of the brain, reducing psychotic or manic symptoms and preventing them from returning. 
Ker dopamin in 5-hidroksitriptamin sodelujeta pri shizofreniji in bipolarni motnji, aripiprazol pomaga normalizirati delovanje možganov, zmanjšati psihotične ali manične simptome in preprečiti njihov ponoven pojav.
Aripiprazole Accord is available as tablets (5, 10, 15 and 30 mg) and can only be obtained with a prescription. 
Zdravilo Aripiprazol Accord je na voljo v obliki tablet (5, 10, 15 in 30 mg) in se izdaja le na recept.
For further information, see the Summary of Product Characteristics (also part of the EPAR). 
Za več informacij glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
The Committee recommended that Aripiprazole Accord be approved for use in the EU. 
Priporočil je, da se zdravilo Aripiprazol Accord odobri za uporabo v EU.
In addition, the company that markets Aripiprazole Accord will provide educational materials to be supplied to patients or their caregivers and to doctors to explain the safe use of the medicine in patients between 13 and 17 years. 
Poleg tega bo družba, ki trži zdravilo Aripiprazol Accord, priskrbela izobraževalno gradivo, ki ga bodo prejeli bolniki ali njihovi negovalci ter zdravniki, v katerem bo pojasnjena varna uporaba zdravila pri bolnikih, starih od 13 do 17 let.
This is a summary of the European public assessment report (EPAR) for Aripiprazole Accord. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Aripiprazol Accord.
• bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood. 
• bipolarno motnjo I, tj. duševno boleznijo, pri kateri ima bolnik manične epizode (obdobja nenormalno privzdignjenega razpoloženja), ki se izmenjujejo z obdobji normalnega razpoloženja.
What measures are being taken to ensure the safe and effective use of Aripiprazole Accord? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Aripiprazol Accord?
A risk management plan has been developed to ensure that Aripiprazole Accord is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Aripiprazol Accord je bil pripravljen načrt obvladovanja tveganj.
The dose should be adjusted in patients who are taking other medicines that affect the way Aripiprazole Accord is broken down in the body. 
Odmerek je treba prilagoditi pri bolnikih, ki jemljejo druga zdravila, ki vplivajo na presnovo zdravila Aripiprazol Accord v telesu.
Aripiprazole is thought to act mainly by being a ‘partial agonist' for the receptors for the neurotransmitters dopamine and 5hydroxytryptamine (also called serotonin). 
Aripiprazol domnevno deluje predvsem kot „delni agonist“ receptorjev za živčna prenašalca dopamin in 5-hidroksitriptamin (imenovan tudi serotonin).
This means that Aripiprazole Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Abilify. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Abilify.
What are the benefits and risks of Aripiprazole Accord? 
Kakšne so koristi in tveganja, povezani z zdravilom Aripiprazol Accord?
Aripiprazole Accord is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults who have responded to the medicine in the past. 
Zdravilo Aripiprazol Accord se uporablja pri odraslih za zdravljenje zmernih in hudih maničnih epizod ter za preprečevanje pojava novih maničnih epizod pri odraslih, ki so se v preteklosti že odzvali na zdravilo.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Accord has been shown to have comparable quality and to be bioequivalent to Abilify. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Aripiprazol Accord primerljivo raven kakovosti kot zdravilo Abilify ter da mu je biološko enakovredno.
Because Aripiprazole Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Aripiprazol Accord generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Aripiprazole Accord is used in patients aged 15 years or over; 
Zdravilo Aripiprazol Accord se uporablja pri bolnikih, starejših od 15 let;
What is Aripiprazole Accord and what is it used for? 
Kaj je zdravilo Aripiprazol Accord in za kaj se uporablja?
This means that aripiprazole acts like dopamine and 5hydroxytryptamine by activating these receptors, but less strongly than the neurotransmitters. 
To pomeni, da aripiprazol z aktiviranjem teh receptorjev deluje kot dopamin in 5-hidroksitriptamin, vendar šibkeje kot živčni prenašalci.
Aripiprazole Accord is a medicine used in patients with the following mental illnesses: 
Zdravilo Aripiprazol Accord se uporablja pri bolnikih z naslednjimi duševnimi boleznimi:
For more information about treatment with Aripiprazole Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Aripiprazol Accord preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Because Aripiprazole Accord is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Abilify. 
Ker je zdravilo Aripiprazol Accord generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Abilify.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aripiprazole Accord, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Aripiprazole Accord aripiprazole 
Aripiprazol Accord aripiprazol
Aripiprazole Accord contains the active substance aripiprazole and is a ‘generic medicine'. 
Zdravilo Aripiprazol Accord vsebuje zdravilno učinkovino aripiprazol in je „generično zdravilo“.
It is not intended to provide practical advice on how to use Aripiprazole Accord. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Other information about Aripiprazole Accord 
Druge informacije o zdravilu Aripiprazol Accord
For treating manic episodes in bipolar disorder, the recommended starting dose in adults is 15 mg once a day, either on its own or in combination with other medicines. 
Za zdravljenje maničnih epizod pri bipolarni motnji pri odraslih je priporočeni začetni odmerek 15 mg enkrat na dan, ki se jemlje samostojno ali v kombinaciji z drugimi zdravili.
For practical information about using Aripiprazole Accord, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Aripiprazol Accord naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The active substance in Aripiprazole Accord, aripiprazole, is an antipsychotic medicine. 
Zdravilna učinkovina v zdravilu Aripiprazol Accord, aripiprazol, je antipsihotično zdravilo.
Therefore, the CHMP's view was that, as for Abilify, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi enako kot pri zdravilu Abilify odtehtajo znana tveganja.
For schizophrenia, the recommended starting dose is 10 or 15 mg per day in adults, followed by a ‘maintenance' dose of 15 mg once a day. 
Pri shizofreniji je priporočeni začetni odmerek pri odraslih 10 ali 15 mg na dan, ki mu sledi „vzdrževalni odmerek“ v višini 15 mg enkrat na dan.
Aripiprazole Accord is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over. 
Zdravilo se uporablja do največ 12 tednov tudi za zdravljenje zmernih do hudih maničnih epizod pri bolnikih, starejših 13 let.
In patients aged between 15 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day. 
Pri bolnikih, starih od 15 do 17 let, je začetni odmerek 2 mg na dan (pri čemer se uporablja zdravilo z aripiprazolom v tekoči obliki), postopoma pa se povečuje na priporočeni odmerek 10 mg enkrat na dan.
Why is Aripiprazole Accord approved? 
Zakaj je bilo zdravilo Aripiprazol Accord odobreno?
For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day. 
Za zdravljenje maničnih epizod pri bolnikih, starih od 13 do 17 let, je začetni odmerek 2 mg na dan (pri čemer se uporablja zdravilo z aripiprazolom v tekoči obliki), ki se postopoma povečuje na priporočeni odmerek 10 mg enkrat na dan. Zdravljenje ne sme biti daljše od 12 tednov.
How is Aripiprazole Accord used? 
Kako se zdravilo Aripiprazol Accord uporablja?
How does Aripiprazole Accord work? 
Kako zdravilo Aripiprazol Accord deluje?
How has Aripiprazole Accord been studied? 
Kako je bilo zdravilo Aripiprazol Accord raziskano?
Further information on Remicade can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Remicade. 
Nadaljnje informacije o zdravilu Remicade so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Remicade.
Remicade received a marketing authorisation valid throughout the EU on 13 August 1999. 
Za zdravilo Remicade je bilo 13. avgusta 1999 izdano dovoljenje za promet, veljavno po vsej Evropski uniji.
What measures are being taken to ensure the safe and effective use of Remicade? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Remicade?
The European Medicines Agency decided that Remicade's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Remicade večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The effects of adding Remicade to existing treatment have also been studied in 103 children and adolescents with Crohn's disease who were aged between 6 and 17 years. 
Učinke dodajanja zdravila Remicade obstoječemu zdravljenju so proučevali tudi pri 103 otrocih in mladostnikih s Crohnovo boleznijo, starih od šest do 17 let.
Other information about Remicade 
Druge informacije o zdravilu Remicade
Patients who receive Remicade must be given a special reminder card. 
Bolniki, ki prejemajo zdravilo Remicade, morajo prejeti posebno opozorilno izkaznico.
As for all medicines, data on the use of Remicade are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Remicade stalno spremljajo.
Remicade is usually given as 3 mg per kilogram body weight in rheumatoid arthritis, although the dose can be increased if necessary. 
Zdravilo Remicade se pri revmatoidnem artritisu običajno daje v odmerku 3 mg na kilogram telesne mase, vendar se odmerek po potrebi lahko poveča.
What benefits of Remicade have been shown in studies? 
Kakšne koristi je zdravilo Remicade izkazalo v študijah?
Why is Remicade authorised in the EU? 
Zakaj je zdravilo Remicade odobreno v EU?
The dose is 5 mg per kilogram for the other diseases. 
Za zdravljenje drugih bolezni znaša odmerek 5 mg na kilogram telesne mase.
A sixth study in 508 adult patients looked at the number of patients whose symptoms improved and who did not need additional treatment with corticosteroids (other medicines used in Crohn's disease). 
Šesta študija je pri 508 odraslih bolnikih beležila število bolnikov, pri katerih so se simptomi izboljšali in ki niso potrebovali dodatnega zdravljenja s kortikosteroidi (drugimi zdravili za zdravljenje Crohnove bolezni).
What is Remicade and what is it used for? 
Kaj je zdravilo Remicade in za kaj se uporablja?
Remicade is also used in patients aged between 6 and 17 years with severe, active Crohn's disease or severely active ulcerative colitis, when they have not responded to or cannot take other medicines or treatments. 
Zdravilo Remicade se uporablja tudi pri bolnikih v starosti med šest in 17 let z resno, aktivno Crohnovo boleznijo ali resnim, aktivnim ulceroznim kolitisom, kadar se na drugo zdravljenje ali zdravila niso odzvali ali kadar jih ne smejo prejemati.
What are the risks associated with Remicade? 
Kakšna tveganja so povezana z zdravilom Remicade?
An overview of Remicade and why it is authorised in the EU 
Pregled zdravila Remicade in zakaj je odobreno v EU
In a study with 60 children aged between 6 and 17 years with ulcerative colitis 73% of patients responded to treatment with Remicade at week eight (44 out of 60). 
V študiji s 60 otroki, starih od šest do 17 let, z ulceroznim kolitisom se je po osmem tednu na zdravljenje z zdravilom Remicade odzvalo 73 % (44 od 60) bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Remicade have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Remicade upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The most common side effects with Remicade (seen in more than 1 patient in 10) are viral infections (such as flu or cold sores), headache, upper respiratory tract infection (colds), sinusitis (inflammation of the sinuses), nausea (feeling sick), abdominal pain (stomach ache), infusion-related reactions and pain. 
Najpogostejši neželeni učinki zdravila Remicade (opaženi pri več kot enem bolniku od 10) so virusne okužbe (na primer gripa ali herpes), glavobol, okužbe zgornjih dihal (prehladi), sinusitis (vnetje sinusov), navzeja (slabost), bolečine v trebuhu, reakcije, povezane z infuzijo, in bolečine.
Side effects reported with Remicade are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Remicade, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
For more information about using Remicade, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Remicade glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Most of the patients showed a reduction in symptoms after adding Remicade to their existing treatment. 
Pri večini bolnikov je bilo opaziti zmanjšanje simptomov po dodajanju zdravila Remicade obstoječemu zdravljenju.
In Crohn's disease in adults, Remicade was compared with placebo (a dummy treatment) in 1,090 adults in four studies. 
Pri Crohnovi bolezni so zdravilo Remicade primerjali s placebom (zdravilom brez zdravilne učinkovine) pri 1 090 odraslih v štirih študijah.
Remicade must not be used in patients with tuberculosis, other severe infections, or moderate or severe heart failure (an inability of the heart to pump enough blood around the body). 
Zdravilo Remicade se ne sme uporabljati pri bolnikih s tuberkulozo, drugimi hudimi okužbami ali zmernim do hudim srčnim popuščanjem (stanjem, pri katerem srce ne zmore prečrpavati dovolj krvi skozi telo).
Remicade has been studied in a total of 1,432 patients with rheumatoid arthritis in two studies. 
Zdravilo Remicade so pri zdravljenju revmatoidnega artritisa proučevali v dveh študijah s skupno 1 432 bolniki.
The active substance in Remicade, infliximab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific structure (called an antigen) in the body. 
Učinkovina v zdravilu Remicade, infliksimab, je monoklonsko protitelo, tj. vrsta beljakovine, ki je bila zasnovana tako, da prepozna določeno strukturo (imenovano antigen) v telesu in se veže nanjo.
To reduce the risk of infusion-related reactions, patients may be given other medicines before or during treatment with Remicade or the infusion time may be slowed down. 
Za zmanjšanje tveganja za pojav reakcij, povezanih z infundiranjem, utegnejo bolniki pred zdravljenjem z zdravilom Remicade ali med njim prejemati druga zdravila ali pa se čas infundiranja upočasni.
Remicade must not be used in patients who have experienced hypersensitivity (allergy) to infliximab in the past, or who are hypersensitive (allergic) to mouse proteins or any of the other ingredients of Remicade. 
Zdravila Remicade ne smejo uporabljati osebe, pri katerih je v preteklosti prišlo do preobčutljivosti (alergije) na infliksimab, ali pri tistih, ki so preobčutljivi za (alergični na) na mišje beljakovine ali katero koli drugo sestavino zdravila Remicade.
It is usually used when other medicines or treatments have failed, in adults with the following diseases: 
Navadno se uporablja pri odraslih z naslednjimi obolenji, kadar druga zdravila ali zdravljenja niso bila učinkovita:
Ulcerative colitis, ankylosing spondylitis and psoriatic arthritis For ulcerative colitis (728 adults), ankylosing spondylitis (70 adults) and psoriatic arthritis (104 adults), Remicade has been compared with placebo. 
Pri ulceroznem kolitisu (728 bolnikov), ankilozirajočem spondilitisu (70 bolnikov) in psoriatičnem artritisu (104 bolniki) so zdravilo Remicade primerjali s placebom.
The patients were treated for 6 months with Remicade, another medicine azathioprine, or the combination of Remicade and azathioprine. 
Bolnike so šest mesecev zdravili z zdravilom Remicade, azatioprinom (drugim zdravilom) ali s kombinacijo zdravila Remicade in azatioprina.
The card will include safety information about the medicine and a record of the dates and results of specific tests that the patient has had so these can be shared with any treating doctor. 
Na njej so povzeti podatki o varnosti zdravila ter evidenca datumov in rezultatov posebnih preizkusov, ki jih je bolnik moral opraviti, ki se lahko dajo na vpogled lečečemu zdravniku.
In these studies Remicade produced a greater improvement in symptoms, led to fistulae healing in more patients and increased the time that patients continued to respond to treatment. 
V teh študijah je zdravilo Remicade v primerjavi s placebom privedlo do večjega izboljšanja simptomov, ozdravljenja fistul pri večjem številu bolnikov ter podaljšalo čas odzivanja bolnikov na zdravljenje.
Remicade alone and in combination with azathioprine was more effective than azathioprine alone. 
Zdravilo Remicade kot samostojno zdravilo in v kombinaciji z azatioprinom je bilo učinkovitejše od samostojnega zdravljenja z azatioprinom.
In a study in 627 adults with psoriasis, Remicade led to a greater improvement in symptoms than placebo. 
V študiji, v katero je bilo vključenh 627 odraslih s psoriazo, je zdravilo Remicade v primerjavi s placebom privedlo do večjega izboljšanja simptomov.
Remicade can only be obtained with a prescription and must be given under the supervision and monitoring of a specialised doctor who has experience in the diagnosis and treatment of the diseases that Remicade can be used to treat. 
Predpisovanje in izdaja zdravila Remicade je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolezni, za katere se to zdravilo uporablja.
• Crohn's disease (a disease causing inflammation of the digestive tract), when the disease is moderate to severe or fistulising (with the formation of fistulae, abnormal passageways between the gut and other organs); 
• Crohnovo boleznijo (obolenjem, ki povzroča vnetje prebavnega trakta), kadar je obolenje zmerno do močno izraženo ali pa prihaja do fistulizacije (s pojavljanjem fistul, tj. nenormalnih prehodov med črevesjem in drugimi organi);
Remicade is used with methotrexate (a medicine that acts on the immune system); 
Zdravilo Remicade se uporablja skupaj z metotreksatom (zdravilom, ki učinkuje na imunski sistem);
In these studies, more patients taking Remicade in combination with methotrexate showed a reduction in symptoms than those taking methotrexate alone, as well as less damage to the joints and greater improvements in physical function. 
V teh študijah je do zmanjšanja simptomov prišlo pri večjem številu bolnikov, ki so zdravilo Remicade prejemali skupaj z metotreksatom, kot pri bolnikih, ki so prejemali samo metotreksat, manj je bilo tudi poškodb v sklepih in opaženo večje izboljšanje telesne zmogljivosti.
This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Remicade is used to treat. 
Ta prenašalec sodeluje pri povzročanju vnetja in ga je mogoče v velikih koncentracijah najti pri bolnikih z obolenji, za zdravljenje katerih se uporablja zdravilo Remicade.
Remicade is an anti-inflammatory medicine. 
Zdravilo Remicade je protivnetno zdravilo.
More adult patients receiving Remicade had a reduction in symptoms than those receiving placebo. 
Zmanjšanje simptomov je bilo opaziti pri več odraslih bolnikih, ki so prejemali zdravilo Remicade, kot pri tistih, ki so prejemali placebo.
Remicade is available as a powder that is made up into a solution for infusion (drip into a vein). 
Zdravilo Remicade je na voljo je v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije v veno).